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Abstract
The Role of Stress-Activated Protein Kinases in ParasitesLymphatic filariasis and leishmaniasis are neglected tropical diseases that are caused by nematode and protozoal parasites. These diseases cause disfiguration, leaving their host socially marked, and in some cases cause more severe disease that can lead to death. These infections, which tend to persist for long periods of time, also lead to bacterial and fungal co-infections, which further exacerbate the disease. Currently there are insufficient treatment options. Current therapies are often too expensive, have toxicity associated with them and are subjected to growing resistance amongst parasite populations. In this thesis I investigated two potential drug targets. The first, is the parasitic nematode Brugia malayi (B. malayi), the causative agent of lymphatic filariasis, and the second, is the protozoal parasite Leishmania mexicana (L. mexicana), one of the causative agents of leishmaniasis. These targets are protein kinases which play critical roles in protecting these parasites from host immune responses and other forms of stress. They are termed, B. malayi, Bm-JNK and L. mexicana, Lmx-MPKl. I have expressed and purified recombinant Bm-JNK and Lmx-MPKl, characterized both kinases and established assays for both suitable for high-throughput drug screening. In addition, I have identified a novel pathway responsible for activation of Lmx-MPKl.
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Introduction
Parasitic disease
Neglected parasitic diseases take a heavy toll economically, psychologically and socially in 
endemic areas. The disease burden as expressed disability-adjusted life years (DALYs), is 
staggering. Disability-adjusted life years (DALYs) are the sum of life years lost through early 
death and life years lost through disability. The total neglected tropical disease (NTD) burden 
is 56.6 million individuals. The NTD burden exceeds that of tuberculosis (34.7), malaria (46.5) 
and is more than half of HIV/AIDS (84.5) [1]. The focus of this thesis is on two diseases, 
lymphatic filariasis, which is caused by the parasitic nematode, Brugia malayi (B. malayi) and 
leishmaniasis, which is caused by the protozoal parasite, Leishmania mexicona (L. mexicana).
Brugia malayi JNK
The World Health Organization (n.d.) estimates that currently 120 million people are 
infected with lymphatic filariasis and 1 billion are at risk [2]. Although most infected people 
will never experience any pathological symptoms, a significant percentage will develop 
severe inflammation of the lymphatic system that pathologically manifest itself as hydrocele, 
lymphedema, and elephantiasis [2]. In addition, the infection is accompanied by secondary 
infections that are caused by bacteria and fungi. Mosquitos are pivotal in transmitting the 
disease. When a mosquito takes a blood meal from an infected person it takes up an 
immature larval form of the parasite called microfilariae (MF). MFs molt in the mosquito gut 
to become LI larvae and further into infectious L3 larvae. The infectious larvae travel to the 
mosquito's proboscis and with the next blood meal the larvae are introduced with the saliva 
into the host. In the host, the parasite counteracts innate and humoral immune responses
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and eventually develops into an adult (female and male), which resides in the lymphatic 
system. The adult female worm can produce thousands of MFs a day, which are released 
into the bloodstream (figure 1).
Figure 1
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Programs are in place for the global elimination of lymphatic filariasis mainly through 
vector prevention, mass drug administration (MDA), and hygienic measures during 
advanced infectious stages [3]. Current drug treatments are insufficient in clearing the 
infection, as drugs mostly eliminate microfilaria and are ineffective against the adult 
worms. The main classes of drugs used to treat lymphatic filariasis are albendazole, diethyl
carbamazine (DEC), ivermectin and deoxycyline [4]. Ivermectin (IVM) can lead to severe
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allergic reactions in some individuals, has safety constraints where the filarial parasite Loa 
loa is co-endemic [5], and has been subject to resistance because of its frequent usage in 
MDA programs [6]. More recently the antibiotic, deoxycyline, has been used to treat 
filariasis [4]. Filarial parasites harbor a symbiotic bacteria called, Wolbachia, which appears 
to play a major role in both reproduction and parasite development [7]. However, 
deoxycyline has a lengthy course of treatment (6-8weeks) and contraindicated for children 
under eight and pregnant women [8]. The current need is to find a new drug that has a 
short period of administration, is effective against adult B. malayi parasites and is safe for 
all groups, including children and pregnant women. B. malayi has evolved a spectrum of 
mechanisms to counteract host immune responses that are mediated through kinases.
One potential target identified previously in our laboratory is a parasitic protein kinase 
called Bm-MPKl [9]. Kinase pathways in humans are known to be important regulators of 
stress responses; in addition they are the main regulators of T helper cell differentiation 
cytokine production [12]. Bm-MPKl, the human ortholog of p38, was found to play a 
critical role in protecting B. malayi from oxidative stress [9]. Further, the parasite expresses 
a variety of factors during its lifecycle that counteract the human immune attack against 
the parasite [10,11].
Model organisms such as C. elegans are useful in understanding protein 
interactions in eukaryotic systems. The power of C. elegans lies in the ability to perform 
"knock-downs" through the use of RNAi, something not possible with parasitic nematodes. 
Two important stress-activated MAPK have been implicated in a variety of protective anti­
stress responses in C. elegans. Using this approach it has been demonstrated that the C.
elegans stress-activated protein kinase, PMK-1, most closely related to Bm-MPKl, is
© 8
essential for anti-oxidative stress responses and innate immunity [39]. A second stress-
activated,y/?/r-l, is required for coordinated movement [12] and hypersensitivity to heavy 
metal stress [13].
The genome of B. malayi has been sequenced [14]. Using the information gained 
from C. elegans, two stress-activated protein kinase orthologs were identified in B. malayi. 
Mentioned previously, a C. elegans PMK-1 ortholog has been identified in B. malayi and 
demonstrated to play an important role in protecting the parasite from ROS. An ortholog 
of C. elegans jnk (Bm-JNK) is also present in B. malayi. My goal was to express and 
characterize Bm-JNK in order to develop a screening assay for inhibitor development. Like 
Bm-MPKl, Bm-JNK may represent a therapeutic target for treating filariasis.
Methods
Expression and Purification of Bm-JNK-His
Bm-JNK-sumo was chemically synthesized and sub-cloned into a Gateway p221ENTR 
vector (Invitrogen). The Bm-JNK-sumo gene was introduced into a Gateway® pDEST™17 
expression vector, containing a 6XHis epitope tag, by in vitro recombination reaction 
according to the manufacturers protocol (Invitrogen). One Shot® BL21(DE3) cells (Life 
Technologies) were transformed with the plasmid construct according to the 
manufacturer's protocol. Three colonies were selected from an agar plate containing 100 
ug/ml carbenicillin and grown overnight in LB broth at 37°C. The culture was induced at 
37°C with 1 mM IPTG and grown for 4 hours. The pellet was collected in a Beckman 
centrifuge at 5,000 x g for 10 minutes. The pellet was frozen and stored at -80°C. Cells 
were lysed with B-PER® Bacterial Protein Extraction Reagent (Pierce) containing Halt 
Protease Inhibitor Cocktail (Pierce Biotechnology, Inc). The mixture was centrifuged at
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21,000 x g for 15 minutes at 4°C. The supernatant was incubated with pre-equilibrated 
wash buffer (50 mM Hepes, 500 mM NaCI, 5 % glycerol, and 10 mM Imidazole pH 7.5) and 
HisPur™ Cobalt Resin (Pierce) for 30 min. The mixture was loaded onto a gravity column 
and the flow through collected. The resin was washed with wash buffer until no more 
protein eluted from the column which was monitored with Coomassie blue stain. The 
protein was eluted with elution buffer (50 mM Hepes, 500 mM NaCI, 150 mM Imidazole,
5 % glycerol, pH 7.5) and fractions were collected. Samples were run on a SDS-page gel 
and subjected to Western blot analysis. In order to remove the Imidazole from the protein 
fractions, the buffer was exchanged (150 mM Hepes, O.lmM EDTA, and 500mM NaCI) in a 
5000 MWCO concentrator (Millipore). The enzyme concentration (0.22 mg/ml) was 
determined with a Nanodrop 2000cc. The protein was stored at -20°C.
ADP-Glo™ assay
The enzyme activity of Bm-JNK was determined by running 5ul containing 1-63 ng of enzyme along with 1.0 ug/ul MBP (MAP kinase substrate) and 0.25 mM MgCh, 2.5 mM DTT and 10 uM ATP. The enzyme was diluted (1:2) with 5 uL of substrate in kinase 
buffer (10 mM Tris-HCI, pH 7.2, 10 mM MgCh, 0.05% NaNs).The ADP-Glo™ assay was run 
according to the manufacturer protocol. For the inhibition assay, commercial inhibitors 
(JNKi, SP600125, TCS, RWJ 67567 active and inactive, TMCb, AG126, FRI8264, MK20alpha, 
SB203580 and Staurosporine) were prepared at 10 uM inhibitor concentration and pre­
incubated with enzyme for 30 minutes at 4°C. 5 uL of substrate were added to the plate 
and incubated (as described above) and read overnight.
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Results
Expression of Recombinant Bm-JNK
Past attempts to purify recombinant Bm-JNK-GST in E. coli were problematic due to 
insoluble protein formation in inclusion bodies and restricted binding access of the GST to 
the glutathione resin. To overcome these issues, I decided to use the new small ubiquitin- 
like modifier (or SUMO) fusion partner system. Intracellularly, SUMO is attached to 
proteins stabilizing them and allowing them to be expressed in the soluble fraction 
instead of inclusion bodies [15]. Besides the advantage of producing a soluble protein 
fraction, the SUMO tag is only 11.5 kDa and can be used with either GST or HIS affinity 
tags. Another advantage of the SUMO fusion partner is that a selective SUMO protease 
recognizes the three dimensional structure of the protein instead of an amino acid 
sequence, making it virtually impossible to cleave a protein at random sites. Unlike other 
proteases, SUMO protease cleaves off the entire SUMO tag leaving the native form of the 
protein of interest [15]. This makes it a good choice for generating protein for crystal 
structure determination. With minimal optimization of the new construct, the first Bm- 
JNK-Sumo-His expression and purification yielded enough protein to initiate an inhibitor 
screen.
Assay Development for Bm-JNK
The first attempt to develop an assay for Bm-JNK involved using the IMAP fluorescence 
polarization assay previously used in the laboratory [9]. Interestingly, when purified Bm- 
JNK was assayed using an EGFR peptide, that is considered a typical JNK substrate, no 
enzymatic activity was observed. However, activity can be shown with a p38tide peptide 
which, as the name implies, is recognized by human p38. In contrast, when screening
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active human JNK1 alpha against EGFR and p38 tide, activity can be shown with EGFR but 
not with p38tide (data not shown). These results indicate that the "insert" (discussed 
below) amongst other substitutions in B. malayi, might be important for the p38tide 
substrate recognition. These finding were confirmed with Predikin sequence alignment 
software (http://predikin.biosci.uq.edu.au), as the program predicts that p38tide is a Bm- 
JNK substrate and not EGFR.
Structural Analysis of Bm-JNK
B. malayi JNK differs from the human and C. elegans forms by a large insert that was up 
until now uncharacterized (Figure 2). With careful analysis, one can see that this insert is a 
duplication of its own sequence. A similar sequence is found in all MAP kinase members; 
p38, JNK, and ERK. The question becomes, is the Bm-JNK duplication, a human like p38 
insert or a JNK 3 like insert (See appendix) which might explain that EGFR as a substrate is 
not recognized in the IMAP assay. All three of the alignments are very similar and cover 
the entire sequence of the insert. In conclusion, it is not important what the best 
alignment looks like, but which amino acids are essential for substrate recognition and/or 
catalysis.
© 12
CL’JSTA L fo rm a t a lig n m e n t by MAFFT (v7 . 149b)
t r !ABQ111 BmJNKt r IA8Q111 i n s c i
t r IA8Q111 i BmJNKt r !ABQ111 i n s c i
t r |A8Q111 BmJNKt r IA8Q111 i n s c i
t r IABQ111 BmJNKt r IA8Q111 i n s c i
t r IABQ111 BmJNKt r IA8Q111 i i n s c i
rt K IA8Q111 BmJNKt r IA8Q111 1 i n s c i
t r IA8Q111 BmJNKt r IABQ111 i n s c i
t r IA8Q111 BmJNKt r IA8Q111 i n s c i
rt n IA8Q111 BmJNKt r IA8Q111 i n s c i
t r j A8Q111 BmJNKt r IA80H 1 i n s c i
MILCLQKLGSSNSGGRDDYETEAILLDSCASVLQPSY1EGVYPA5.XA5TSTA5EFYNVDI
NDTRLCVLKRYQNLRIIGSGAQGVVCAAKGTLRGEQVAIKXLSRPFQNVTnAKRAYREFK
Ly.NLVNHKN:iGLLNAFTP0KTLDEFSDlYIVMElMDANLCQVIC^iDL3HERy.SYLLY0M
LCG1RHLHAAGIIHRDLKPSNIWKSDCSLKILDFGLARSAGDSFKMTPYWTRYYRAPE
VILGMGYKDNDIVLALVAVDVWSTGCIFGEMIRGSVLFPGNDHIGQWTKIVEQLGTPSLM
......... ..... LTVDIWSIGCIFGELIRGRVLFPGTDHIDQWSKIIEQLGTPGRD
• • # # • * *  * * * * * * * * * *  * * * • • * * * * * * * * * * * * * * * *
FKRRLQSTVRNYVENRPHFPGFPF3KLFPDELFPALSSSDSRLTVDIW5IGCIFGELIRG
FMQKLQATVRSYVENRPRHPGLPFEILFSD----------- LTVDIKSIGCIFGELIRG
* * • • * * • * • *  **** * * *  ****** * * * * * * * * * * * * * * * * * * * * *
RVLFPGTDKIDQWSKIIEQLGTPGRDFXQXLOATVRSYVENRPRHPGLPFEILFSDNIFP
RVLF PGT DKIDQWSK11EQLGT PGRDFMQ KLQATVRS YVEN RPRHPGLP FEILF SD---
* * * * * * *  * * * * * * * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * *
KPATNNALCPAOARBLISXMLVIBPEKRISVDEALXaPYVYVWFGEAEVYAPPPEQYNHS
IDSRGaiVECWKELIFKEIMQYECTaDEYGVKXSINGES GAVP555 S S F QNNEKGDC5T ?
GNTLVTNGL
Fig. 2: Sequence alignment with CLUSTAL by MAFFT (v7.149b) Bm-JNK with insert duplication is shown above.
A second assay system (ADP-Glo™, Promega) was also evaluated. An advantage of the ADP- 
Glo™ assay is that it can utilize protein substrates, which are typically better substrates than 
peptides. Bm-JNK demonstrated excellent activity using this assay with myelin basic protein 
(MBP) as a substrate (Figure 3). The human JNK inhibitors JNKi, SP600125, TCS, active and 
inactive RWJ 67567, TMCb, AG126, FRI8264, MK20alpha, SB203580 and Staurosporine are
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potent inhibitors of human JNKs, but show little or no inhibition against Bm-JNK (Table 1).
Bm-JNK (ng)
Figure 3: ADP-Glo™ Bm-JNK activity curve against MBP with Mg2+ as a cofactor. 
Good activity can be shown at these concentrations.
In h ib ito r %  In h ib itio n In h ib ito r %  In h ib itio n
JNKi 3.77 MK20 20.39
SP600125 5.42 SB203580 16.83
TCS 11.55 Staurosporine 14.10
RWJ67567a -0.38 AG126 4.43
RWJ67567i -2.78 FRI8264 -1.41
TMCB 22.36
Table 1: ADP-Glo™ kinase assay. Percent inhibition of selected inhibitors (lOuM) against Bm-JNK.
Human JNK, p38, and ERK inhibitor show little or no inhibition against Bm-JNK.
DiscussionUnlike Bm-MPKl kinase which is inhibited by know p38 kinase inhibitors, Bm-JNK appears to be much more restrictive with regards to human JNK inhibitors. A kinase might only recognize a limited number of substrates [16,17]. Motif recognition is just as important as recruitment. If the affinity of a substrate is low a reaction might only occur when the activated enzyme concentration is high. Zhu, Liu, and Shaw (2004) suggest that
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this might be an indirect way of regulating signaling. In homogenous in vitro assays, phosphatases are absent and a higher active enzyme population can be reached, making it easier to overcome the threshold of substrate recruitment [17]. Substrate recognition can also be different amongst isoforms, as is the case for human c-Jun terminal kinase, namely JNK 1, JNK 2, and JNK 3 [18]. Substrate recognition varies among all three isoforms [16]. JNK distribution is different in the human body, where JNK 1 (48%] and JNK 2 (46%) are mostly found in cells and tissues and JNK 3 in the brain, implying different functions for each of them. Bm-JNK resembles most closely human JNK 3 (51%). Since many of the amino acids within the sequence are substituted in Bm-JNK, substrates will probably be different for the parasitic protein. The importance of the interaction of certain amino acid on recognition is not only important for JNK 1 substrates; they also play a major role in the recognition of upstream activators. When Mooney and Whitmarsh (2004) [19] mutated GST-JNK2 (E329A/E331A) in humans, MKK7 but not MKK4 was able to phosphorylate JNK2. In Bm-JNK, when aligned with JNK 2, B. malayi has a tyrosine instead of glutamic acid (E331Y) in the docking site, suggesting that MKK4 is possibly not an upstream activator of Bm-JNK. Bm-JNK has a conserved docking groove for upstream kinase activation that is almost identical to Human-JNK although the position in the kinase is shifted. This indicates similar upstream activators in B. 
malayi as in human JNK. JNK changes conformation as its T-X-Y domain is, depending on the activator, either mono- or dually-phosphorylated by a wide range of upstream activators of MAPKKKS including MEKK1-MEKK4, ASK and MLK [20] and ERK 8 [21]. Hence making other upstream activators of JNK such as MKK4 and MKK7 unsuitable as drug targets as their activation can be bypassed in a non-linear fashion.
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As more structural features become apparent in B. malayi JNK and a valid screening assay against the kinase is developed, it might be possible to find potent inhibitors against this kinase. The human JNK inhibitors are not very potent against Bm-JNK. This could be an important advantage as more selective inhibitors may be developed against the parasitic kinase and not the human isoforms.
A Newly Characterized Stress Pathways in Leishmania Leishmaniasis is a tropical disease that affects more than 1.3 million people worldwide especially in developing countries and 310 million are at risk [22]. Current treatments are expensive [23], often accompanied by severe side effects and subject to a growing number of resistances [24]. The disease can cause skin lesions eventually disfiguring affected people or lead to a more severe visceral form that can potentially lead to death [22]. Leishmania, like other parasites, have evolved mechanisms to deal with various stresses encountered during their life cycle. Stresses are generated during infection by activated macrophages, easinophiles and lymphocytes [25], leading to the generation of reactive oxygen species (ROS) that must be countered in order for parasites to survive. To date little is known about leishmania's stress resistance pathways. One potentially important protein in leishmania's anti-stress response is the protein kinase Lmx-MPKl. Lmx-MPKl is required for parasite viability in vivo [26]. Interestingly, Lmx-MPKl has a closely related ortholog in plants called, MPK3. MPK3 is part of an important anti-stress pathway in plants [27] consisting of the proteins OXI1, NDPK2 and MPK3. Nucleoside diphosphate kinase 2 [NDPK 2) is a well-studied signaling protein in plants and is known to increase stress resistance in Arabidopsis [28] and sweet potatoes plants. Genetic modifications on sweet potato plant, NADPK 2, is on itsway to increase overall product yield through the increase of stress resistance [29]. A© 16
bioinformatics examination of the leishmania genome has revealed a similar pathway consisting of 0X11, NDPK2 and Lmx-MPKl. The closest human relative is extracellular regulating kinase 8 (ERK 8), which is also the newest member of the fifteen known human MAP kinases [30]. The stress activated MAP kinase pathway in leishmania is similar to that in plants, which activates anti-oxidative enzymes such as ascorbate peroxidase [APX 1). APX 1 is believed to be involved in the detoxification of light produced hydrogen peroxide [31] and is found in other organisms such as insects and cyanobacteria. In addition glutathione-S-transferase/glutaredoxin (E9APZ6), and 2- oxoglutarate oxygenases (E9AM54), oxidoreductase (E9AMA8) have similar detoxifying functions. All these interactions were inferred from homology.
Methods
Expression and Purification of Lmx-MPKlPlasmid Lmx-MPKl EDY TOPO and Lmx-MPKl TDY TOPO stored at -20°C were transformed into One Shot® BL21(DE3) (Life Technologies) cells on an agar plate containing 100 ug/ml carbenicillin. Colonies were selected and grown in LB broth at 37°C. The culture was induced at 37°C with 1 mM IPTG and 0.1% L-arabinose and grown overnight. The pellet was collected by centrifugation in a Beckman centrifuge at 5,000 x g for 10 minutes. The pellet was frozen and stored at -80°C. The cells were lysed with B- PER® Bacterial Protein Extraction Reagent (Pierce) containing lOOx Halt Protease Inhibitor Cocktail (Pierce Biotechnology, Inc.). The mixture was centrifuged at 21,000 x g for 15 minutes at 4°C. The supernatant was incubated with pre-equilibrated wash buffer (50 mM Hepes, 500 mM NaCl, 5 % Glycerol, 10 mM Imidazole pH 7.5) and HisPur™Cobalt Resin (Pierce) resin for 30 min. The mixture was loaded onto a gravity columnand the flow through collected. The resin was washed with wash buffer until no more© 17
protein eluted from the column which was monitored with Coomassie blue stain. The protein was eluted with elution buffer (50 mM Hepes, 500 mM NaCl, 5 % Glycerol, 10 mM Imidazole pH 7.5) and the fractions were collected and run on an SDS-page gel and subjected to Western blotting. Eluted fractions were combined and subjected to buffer exchange with HEPES 150mM, EDTA O.lmM, NaCl 500mM, in a 5000 MWCO concentrator (Millipore) at 4000g at 4°C. Protein concentration was determined with a Nanodrop 2000cc. at 260nm and was found to be 0.25 mg/ml. The protein was stored at -20°C.
Expression and Purification of Lmx-NDPK2The parasitic NDPK2 gene was chemically synthesized (Invitrogen) and included a TEV protease cleavage site on the N-terminus and sub-cloned into a Gateway p221ENTR vector (Invitrogen). The NDPK2 gene was introduced into a Gateway® pDEST™15 expression vector, containing a GST epitope tag, by an in vitro recombinase reaction according to the manufacturers protocol (Invitrogen). The recombinase reaction was used to transform One Shot® BL21(DE3) cells according to the manufacturers protocol (Life Technologies). Cells were plated on an agar plate containing 100 ug/ml carbenicillin and three colonies were selected and grown in LB-broth overnight at 37°C in an incubator shaker at 220rpm. Cultures were induced with 1.0 mM IPTG and grown at 37°C post induction for 4 hours. The cell pellet was collected using a Beckman centrifuge at 5,000g for 10 minutes. The pellet was frozen and stored at -80°C. Cells were lysed with B-PER® Bacterial Protein Extraction Reagent (Pierce) containing lOOx Halt Protease Inhibitor Cocktail (Pierce Biotechnology, Inc.). The mixture was centrifuged at 21,000 g for 15 minutes at 4°C. The supernatant was incubated with Pierce®Glutathione Agarose (Thermo Scientific) pre-equilibrated with Phosphate Buffered
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Saline (PBS) for 1 hour. The glutathione resin was loaded onto a gravity column and the flow through was collected. The column was washed with PBS until no more protein eluted. The column was washed with five resin volumes of HEPES buffer containing, 25 mM HEPES, pH 7.4,150 mM NaCL, 1.0 mM DTT, 10% glycerol and O.lmM EDTA (Buffer A). The elution buffer was prepared with Buffer A containing 10 mg/ml glutathione. The resin was incubated with elution buffer for 15 minutes and eluted fractions were collected and absorbance was measured at 260 nm with a Nanodrop 2000cc (Thermo Scientific). The protein was stored at -20 °C. SDS-Page and Western blot analysis were conducted as described previously [9].
Immobilized metal affinity-based fluorescence polarization IMAP AssayLmx-MPKl (EDY) mutant activity was assayed using an immobilized metal affinity- based fluorescence polarization (IMAP / Molecular Devices, Sillicon Valley, CA) assay according to the manufacturer's protocol. Enzyme (1-55 ng) was serial diluted in kinase buffer, containing; 10 mM Tris-HCl, 10 mM MgCh, 0.05% NaN3, and 0.01% Tween© 20 (Molecular Devices, Silicon Valley, CA). The substrate (10 ul), p38tide (5FAM- IPTTPITTTYFFFK-NH2), containing 100 uM ATP and 1.0 mM DTT, was added into each well and incubated for 1 hour at 30°C. The reaction was terminated by adding Progressive Binding Reagent (Molecular Devices, Silicon Valley, CA). The assay was read 15 minutes post termination. Inhibitors, when present, were pre-incubated with enzyme for one hour and assayed at 10 uM and 30 uM. Data was analyzed using Microsoft Excel. 
ADP-Glo™ assayParasitic NDPK2, Lmx-MPKl (TDY) and Lmx-MPKl (EDY) enzyme assays (10 ul) contained 1-55 ng of enzyme along with 1.0 ug/ul MBP and 0.25 mM MgCk, 2.5 mM DTTand 10 uM ATP. The ADP-Glo™ assay was run according to the manufacturer protocol. The© 19
plate was read after 30 minutes and overnight. When added, the commercial inhibitor, SP600125 (Sigma-Aldrich), was present at 10 uM and 30 uM. Inhibitors were pre­incubated with enzyme for 30 minutes at 4°C.
Activation of Lmx-MPKl TDY with NDPK2Reaction mixtures (10 ul) contained 31 ng/ul of Lmx-MPKl (TDY) in Buffer A containing 0.13 mM MgCh, 1.0 ug/ul MBP and when present, 0.075-9.75 ng/ul NDPK2. Reactions were incubated at 30°C for 15 minutes. ADP-Glo™ reagent and Kinase detection buffer was were added as described above and read after 30 minutes (Figure 1).The luminescence was read with a Synergy Microplate reader (BioTech, Winooski, VT) and analyzed with Gen5 Data Analysis Software (Bio-Tek) and Microsoft Excel (Figures 2, 3 and 4).
ResultsExpression and purification of NDPK2-GST, Lmx-MPKl-His (TDY), and Lmx-MPKl-His (EDY) produced adequate yields to initiate a kinase screen (Figure 4). Mutation of the activation domain, TDY, to ADY renders the kinase inactive. Mutation EDY renders the kinase constitutively active [35]. Lmx-MPKl wild type was mutated to a constitutively active EDY mutant in order to establish an activity assay (Figure 5 & Methods).
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Figure 4. SDS-Page gels; picture A shows NDPK2-GST at about 43 kDa and co-eluted GST band at 26 kDa. Picture B shows inactive Lmx-MPKl-TDY -His at about 41 kDa and picture C shows constitutively active Lmx-MPKl-EDY-His at 41 kDa.
Figure 5: Lmx-MPKl activity assay with wild type (wt) TDY shows no activity (red squares). The constitutively active mutant Lmx-MPKl (EDY) is active against MBP in the presence of ATP and Mg2+.
Inhibition of Lmx-MPKl by the JNK inhibitor SP600125
L. mexicana MPK1 is a potential drug target (Wiese, 2000) but an inhibitor has not been reported for this enzyme to date. Here I show that a common JNK inhibitor, SP600125, inhibits Lmx-MPK 1 in a dose dependent manner (Figure 6). SP600125 is a reversible ATP competitive inhibitor. Kinase activity was inhibited by 25% at 10 uM and 38% at 30 uM.With the aid of crystal structures, Heo et al. (2004) [37] showed the interactions of the inhibitor with a JNK-interacting protein 1 (JIP peptide fragment) and JNK 1 complex and determined the positioning of the inhibitor to the respective amino acids. According to the authors, SP600125 makes two hydrogen bonds with M e tlll  and Glul09, which are common hydrogen bonds amongst kinases interacting with inhibitors. When aligning JNK -  1 with Lmx-MPK 1 (Accession numbers P45983 and 000872 respectively), Glul09is conserved whereas M e tlll  is substituted for an Isoleucine. The Adenine binding
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pocket has all of the hydrophobic residues conserved (Ile32, Val40, Ala53, and Val86) except for Leul68, which is substituted for a Glycine. The loss of the Leul68 side chain may explain the lower potency of the inhibitor with Lmx-MPKl. The three-dimensional structure of Lmx-MPKl is unknown, but the fact that SP600125 inhibits the kinase weakly indicates that some of the human characteristics are conserved in Lmx-MPKl.
NDPK 2 as an upstream activator of Lmx-MPKl
Leishmania and other kinetoplastids possess several plant-like genes [32]. In recently published articles by Flannery et al. (2013), it is proposed that "Leishmania possesses a plant-like system for the acquisition of iron" [33], and Biyani et al. (2011) showed that plant aquaporins are similar in leishmania [34]. Hence, some of Leishmania's metabolic pathways and structural components are plant-like. Given the similarity between plant MPK3 and leishmania Lmx-MPKl pathways, I hypothesize that one of the potential mechanisms by which Leishmania withstands oxidative stress is by the 0XI1-NDPK2-Lmx-MPK1 plant like pathway mentioned previously. To determine if this is the case I explored the possibility that like in plants, NDPK2 could be a potential upstream activator of Lmx-MPKl. Leishmania does not contain typical MAPK signaling cascades with upstream MAPKKs and the upstream activator of Lmx-MPKl is unknown. Moon et al. (2002) [36] showed that NDPK2 not only bound to MPK3 in Arabidopsis thaliana (At) but also enhanced its kinase activity using myelin basic protein (MBP) as a substrate. It was further demonstrated that plant NDPK2 directly phosphorylates AtMPK3, but not MBP, leading to its activation. Using recombinant leishmania NDPK2 and Lmx-MPKl, I demonstrated activation of wild type (TDY) Lmx-MPKl using an in
© 22
vitro Kinase ADP-Glo™ assay (Promega). As shown in figure 4., NDPK2 activates wild type [TDY] Lmx-MPKl. Unlike plant NDPK2, leishmania NDPK2 also phosphorylâtes MBP (Figure 4].
Figure 6: IMAP inhibition assay in 96 well plate of Lmx-MPKl with SP600125. Blue diamonds show the enzyme signal without any inhibitor. Green triangle shows lOuM of SP600125 addition into each well and the red square shows 30uM of SP600125 addition into each respective well. The enzyme was inhibited by 25% with lOuM and by 38% with the 30uM inhibitor concentration.
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Figure 7: ADP-Glo™ kinase activation assay. Red squares show NDPK2 phosphorylating MBP. Same reaction was run with Lmx-MPKl present in the reaction and an increase in phosphorylation can be observed (blue squares).
ConclusionIn conclusion, I have successfully expressed, purified and established an in vitro kinase assay for Lmx-MPKl suitable for high through-put inhibitor screening. In addition, I identified the first reported inhibitor (SP600125) for this enzyme. A bioinformatic analysis of MAPK kinase pathways in lower organisms and plants revealed a plant stress-signaling pathway present in leishmania (0X1-1, NDPK2 & MPK3). This observation suggested that leishmania NDPK2 might be an upstream activator of Lmx-MPKl. To determine if this was the case I utilized recombinant leishmania NDPK2 and demonstrated direct activation of wild type (TDY) Lmx- MPKl. Here we demonstrated NDPK2 as the first known upstream activator of Lmx-MPKl. The proposed kinase pathway is shown in the appendix.
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Appendix
Two t i m e s  B m -JN K
D IV LA LV A VD  VW ST GCIFGE M IR G SV LFP G  NDHIDQWTKI VEQLGTPSLM  
FMRRLQSTVR NYVENRPHFP GFPFDKLFPD E L F P A D IV L A  LVAVDWSTGC
IF G E M IR G S V  LFPGNDHIDQ WTKIVEQLGT PSLMFMRRLQ STVRNYVENR  
PHFPGFPFDK LFP D E LFP A
241
1
VILGMGYKDNDIVLALVAVDVWSTGCIFGEMIRGSVLFPGNDHIDQWTKIVEQLGTPSLM 
----------DIVLALVAVDVWSTGCIFGEKIRGSVLFPGNDHIDQWTKIVEQLGTPSLM
300
50
A8Q111 A8Q111 3RUMA 
2013100571AR4H7DI1
301
51
FMRRLQSTVRNYVENRPHFPGFPFDKLFPDELFPALS S SDSRLTVDIWSIGCIFGELIRG 
-KRRLQSTVRNYVENRPHFPGFPFDKLFPDELFPADIV— LALVAVDWSTGCIFGEMIRG ********************************** *.. ** ******.***
360
107
A8Q111 A8Q111 3RUKA 
2013100571AR4H7DI1
361
108
RVLFPGTDHIDQWS KlIE QLGTPGRDFMQKLQATVRSYVENRPRHPGLPFEILFS DNIFP 
SVLFPGNDHIDQWTKIVEQLGTPSLMFKRRLQSTVRNYVENRPHFPGFPFDKLFPDELFP 
*****_******.**•******. **•♦**•***.******•.**♦**♦ ** *..**
420
167
A8Q111 A8Q111 3RUKA 
2013100571AR4H7DI1
421
168
KPATNNALCPAQARDLLSKMLVIDPEKRISVDEALKHPYVYVWFDEAEVYAPPPE QYNHS 
A------------------------------------------------------------
480
168
A8Q111 A8Q111 3RUMA 
2013100571AR4H7DI1
Sequence alignment parameters: 
Identical Positions 137 
Identity 24.954%
Similar positions 17
B m -JK K l w i t h  Human p38
D IV LALV A VD  VW ST GCIFGE M IR G SV LFP G  NDHIDQWTKI VEQLGTPSLM
FMRRLQSTVR NYVENRPHFP GFPFDKLFPD ELFPAYNQTV
]LLTGRTLFP GTDHIDQLKL ILR LV G T P G A  E L L K K IS S E S  
1PKMNFANVF I G
DIW SVGCIM A
AR N YIQ SLT Q
241 VILGMGYKDNDIVLALVAVDVWSTGCIFGEKIRGSVLFPGNDHIDQWTKIVEQLGTPSLM 300
1  DIVLALVAVDVWSTGCIFGEMIRGSVLFPGNDHIDQWTKIVEQLGTPSLM 50
**************************************************
301 FMRRLQSTVRNYVENRPHFPGFPFDKLFPDELFPALSSSDSRLTVDIWSIGCIFGELIRG 360
51 -KRRLQSTVRNYVENRPHFPGFPFDKLFPDELFPAYN---- QTVDIWSVGCIKAELLTG 104********************************** . ******.***♦.**• *
361 RVLFPGTDHIDQWS KlIEQLGTPGRDFMQKLQA-TVRS YVE NRPRHPGLPFEILFS DNIF 419 
105 RTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQKPKNNFANVFIG--  161
*#********** , *♦. ***** **♦♦**.* Î.*.*SÎ. ♦ * • * • *
A8Q111 A8 0111_3RUMA
2013100561AIMDHW3Z
A8Q111 A8 Q111_3RUMA
2013100561AIMDHW3Z
A8Q111 A8Q111_3RUKA 
2013100561A1MDBNBI
Sequence alignment parameters: 
Identical positions 118 
Identity 21.455%
Similar positions 26
Bm-ÏNK1 with Human INK 3 insert
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D IV LALV A VD  V W STGCIFGE M IR G SV LFPG  NDHIDQWTKI VEQLGTPSLM  
FMRRLQSTVR NYVENRPHFP GFPFDKLFPD E LFP A VDIWS VGCIMGEMVR  
K ILF P G R D Y  IDQWNKVIEQ LGTPCPEFMK KLQPTVRNYV ENRPKYAGLT  
P K LFP D SLF PA
241 VILGMGYKDNDIVLALVAVDVWSTGCIFGEKIRGSVLFPGNDHIDQWTKIVIQLGTPSLK 
1 ---------- DIVLALVAVDVWSTGCIFGEMIRGSVLFPGNDHIDQWTKIVEQLGTPSLK
I**************************************************
301 FMRRLQSTVRNYVENRPHFPGFPFDKLFPDEliFPALS S SDSRLTVDIWSIGCZFGELIRG
51 -MRRLQSTVRNYVENRPHFPGFPFDKLFPDELFPA---------VDIWSVGCIMGEMVRHw********************************* *****.*■#*♦**. •*
361 RVLFPGTDHIDQWSKIIEQLGTPGRDFMQKLQATVRSYVENRPRHPGLPFEILFSDNIFP 
101 KILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRNYVENRPKYAGLTFPKLFPDSLFP «♦**** *•★***,*♦•#★***** .*#.*** ***,★**♦**•• ** * ** *.♦**
421 KPATNNALCPAQARDLLSKMLVIDPEKRISVDEALKHPYVYVWFDEAEVYAPPPEQYNHS 
161 A........... ...................... -...........................
300 A8Q111 A8Q111 BRUMA
50 2013100551AUSPQ5ZL
360 A8Q111 A8Q111 BRUMA
100 2013100551AUSPQ5ZL
420 A8Q111 A8Q111 3RUMA
160 2013100551AUSPQ5ZL
480 A8Q111 A8Q111 BRUMA
161 2013100551AUSPQ5ZL
Sequence alignment parameters: 
Identical positions 134 
Identity 24.408%
Similar positions 16
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Death,..) Overview of the MAP kinase cascade Leishmania mexicana
Appendix Figure 1: Proposed MAP kinase pathway in leishmania.
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